TG Therapeutics (TGTX) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic focus and market overview

• Focused on B-cell mediated diseases, primarily multiple sclerosis (MS), with Briumvi as the lead product.

• Briumvi is approved globally, available in 16 countries, and has over 20,000 patients treated, mostly in the U.S.

• Competes in the anti-CD20 market, which represents about $10 billion in sales and 50% of the MS dynamic market share.

• Over 97% of top 200 MS centers use Briumvi, which holds about 20% dynamic share in the HCP-administered anti-CD20 segment.

• Aims to become the number one prescribed anti-CD20 for relapsing MS based on dynamic market share.

Financial performance and guidance

• Surpassed $1 billion in cumulative net sales, with $616 million in global revenue and $594 million in U.S. net revenue for the latest year.

• Achieved 90% year-over-year growth and outperformed quarterly targets.

• 2026 global net revenue guidance is $875–$900 million, with $825–$850 million expected from the U.S.

• Core operating expenses targeted at $350 million, with additional one-time costs for subcu Briumvi inventory and manufacturing.

• Significant cash flow and EBITDA expected, with potential for increased share repurchases and accelerating profitability.

Product differentiation and commercial strategy

• Briumvi offers a one-hour infusion every six months, with consistent efficacy and safety over six years.

• Lacks breast cancer and colitis risks, and is glycoengineered for enhanced ADCC.

• Priced as the lowest branded MS treatment, facilitating rapid payer coverage and broad access.

• Won the VA contract, offering the lowest price for veterans in the U.S.

• Customer service and experienced MS-focused team drive adoption and ease of onboarding.